Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells $16,557.75 in Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 3,345 shares of Lexeo Therapeutics stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $4.95, for a total value of $16,557.75. Following the completion of the sale, the chief executive officer directly owned 374,472 shares in the company, valued at $1,853,636.40. This represents a 0.89% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Richard Nolan Townsend also recently made the following trade(s):

• On Wednesday, July 1st, Richard Nolan Townsend sold 25,947 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $4.48, for a total value of $116,242.56.

Lexeo Therapeutics Trading Down 3.6%

Shares of LXEO stock opened at $4.88 on Friday. The stock has a 50 day simple moving average of $4.73 and a 200-day simple moving average of $5.54. The company has a market cap of $400.40 million, a price-to-earnings ratio of -4.24 and a beta of 1.46. Lexeo Therapeutics, Inc. has a 12-month low of $3.99 and a 12-month high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.01). On average, equities analysts forecast that Lexeo Therapeutics, Inc. will post -1.18 earnings per share for the current fiscal year.

Analyst Ratings Changes

LXEO has been the topic of several research analyst reports. Wall Street Zen lowered shares of Lexeo Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, August 15th. Chardan Capital raised Lexeo Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. JPMorgan Chase & Co. lowered their price target on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a report on Thursday, June 25th. Finally, Weiss Ratings raised Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $18.75.

Institutional Investors Weigh In On Lexeo Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Hennion & Walsh Asset Management Inc. purchased a new position in Lexeo Therapeutics during the 2nd quarter valued at about $1,237,000. Dimensional Fund Advisors LP raised its position in Lexeo Therapeutics by 27.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,103,584 shares of the company’s stock worth $6,332,000 after acquiring an additional 240,692 shares during the last quarter. Spruce Street Capital LP lifted its holdings in shares of Lexeo Therapeutics by 430.6% in the first quarter. Spruce Street Capital LP now owns 928,593 shares of the company’s stock valued at $5,330,000 after purchasing an additional 753,593 shares in the last quarter. Affinity Asset Advisors LLC lifted its holdings in shares of Lexeo Therapeutics by 57.8% in the first quarter. Affinity Asset Advisors LLC now owns 5,050,211 shares of the company’s stock valued at $28,988,000 after purchasing an additional 1,850,211 shares in the last quarter. Finally, Orbimed Advisors LLC lifted its holdings in shares of Lexeo Therapeutics by 69.5% in the first quarter. Orbimed Advisors LLC now owns 3,602,450 shares of the company’s stock valued at $20,678,000 after purchasing an additional 1,477,450 shares in the last quarter. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.